Rigel Pharmaceuticals (RIGL) Stock Climbs On COVID-19 News

Rigel Pharmaceuticals RIGL Stock News

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is making a run for the top in the market this morning after announcing positive news surrounding a COVID-19 treatment under development. Here’s the scoop: Rigel Pharmaceuticals Announces Positive Data In a press release issued early this morning, Rigel Pharmaceuticals announced positive topline results from a Phase 2 clinical trial. … Read more

Rigel Pharmaceuticals (RIGL) Stock: Gaining On FDA Approval

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is having a relatively strong start to the trading session this morning, following up on the gains that we saw in the stock late in the market yesterday. The gains are ultimately the result of a late-in-the-day announcement that the FDA approved one of the company’s clinical candidates. Today, well … Read more

Bio-Path (BPTH) Stock: Soaring On Clinical Data And Financial Results

Bio-Path Holdings Inc (NASDAQ: BPTH) is having an overwhelmingly strong start to the trading session this morning, and for good reason. Not only did the company release positive interim clinical data, they also released financial data and a corporate update, all of which seem to be exciting investors. Today, we’ll talk about: The clinical data … Read more

Rigel Pharmaceuticals (RIGL) Stock: Falling On Failed Study

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is having an overwhelmingly rough start to the trading session this morning, and for good reason. The company announced top-line data from a Phase 2 clinical study that missed the mark. Of course, this led to fear among investors who are pushing the stock downward. Today, we’ll talk about: What … Read more

Rigel Pharmaceuticals (RIGL) Stock: NDA Coming Soon!

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Rigel Pharmaceuticals is having a strong day in the market today, and for good reason. At 7 eastern, a report was released surrounding the company’s lead candidate, fostamatinib. In fact, according to today’s release, it looks like the company is on track with previous NDA submission plans, which means that … Read more

Rigel Pharmaceuticals (RIGL) Stock: Here’s Why It’s Sinking!

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Rigel Pharmaceuticals is having an incredibly rough day in the market today, and for good reason. The company released results for the second of two Phase 3 studies, unfortunately missing the primary endpoint. Today, we’ll talk about what we saw from the study results, what we’re seeing from the stock, and … Read more

Rigel Pharmaceuticals (RIGL) Exploding On Positive Study Results

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Rigel Pharmaceuticals is having an incredibly strong day in the market today, and for good reason. The company released positive results from two double-blind Phase 3 clinical studies. Today, we’ll talk about the results, how the market reacted to the news, and what we can expect to see from RIGL … Read more